CELL INTELLIGENCE · 肿瘤细胞治疗研究

CRISPR 基因组编辑与白血病免疫治疗的未来

CRISPR Genome Editing and the Future of Leukaemia Immunotherapy.

虽然碱基编辑在精确性和功能保留方面表现优异，但当需要完全基因敲除时，CRISPR-Cas9 仍是首选。

自相残杀效应驱动的未经编辑 CD7 CAR-T 细胞在 T 细胞白血病中的多组学分析与临床前疗效

Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia.

这些数据支持调整标准生产方案以克服自相残杀的可行性，并证明可规模化、未经编辑的 UMCG-001 细胞用于治疗 T 细胞恶性肿瘤的临床转化潜力。

浆细胞疾病细胞免疫治疗的 2025 年更新

2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.

重编程 CD8⁺ T 细胞分支 N-糖基化限制耗竭并增强细胞毒性与肿瘤杀伤

Reprogramming CD8+ T-cell Branched N-Glycosylation Limits Exhaustion, Enhancing Cytotoxicity and Tumor Killing.

CRISPR/Cas9 TCR 编辑的 NKp30 CAR-T 细胞对表达 B7H6 的白血病与黑色素瘤表现出更强的抗肿瘤免疫

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.

当前抗骨髓瘤 CAR-T 细胞：新型靶点与方法

Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.

头颈部鳞状细胞癌 CAR-T 细胞治疗的进展与挑战

Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.

敲除 SMAD4 以拮抗 TGF-β 和激活素 A 抑制从而增强人 NK 细胞抗肿瘤功能

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression.

非病毒转染系统制备的多重编辑 CAR-T 细胞功能效力增强

Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system.

解析 MYC 介导的对传统抗体与 T 细胞重定向治疗性抗体的逃逸机制

Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies.